ForPatients
by Roche

Breast Cancer Breast Cancer Er-Positive Breast Cancer HER-2 Negative

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Trial Status	Trial Runs In	Trial Identifier
Active, not recruiting	5 Countries	NCT03332797 2017-002083-41 GO39932

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and/or luteinizing hormone-releasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT03332797 2017-002083-41 GO39932
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	>= 18 Years	No

© 2022 F. Hoffmann-La Roche Ltd